Curriculum Vitae: Professor Åsa Petersén, MD PhD

Name	Åsa Petersén
Gender	Female
Date of Birth	October 25, 1974
Work Address	Translational Neuroendocrine Research Unit (TNU), Lund University (LU), BMC D11, 221 84 Lund, Sweden
Phone number	+ 46-46-2221686. E-mail: asa.petersen@med.lu.se
Web page	https://www.huntington-research.lu.se

1. Degree of Doctor

2001 PhD in Neuroscience, LU, Sweden (1997-2001).
Title: Effects of dopamine and excitotoxicity in experimental models of Huntington's disease.
Date: 2001-12-08. *Thesis Supervisor*: Prof. Patrik Brundin, LU.
Faculty opponent: Prof. Anne B. Young, Chair of Neurology, Harvard University, USA.

2. Higher education qualification

2005 MD at LU, Sweden (1994-1997, 2002-2005)
2017 Specialization in Psychiatry (2007-2017)

3. Present Position, since 2017

- **Professor in Medical Research** with specialization in Neuroscience, Medical Faculty, LU and **Senior Consultant in Psychiatry** (30% clinical work), Region Skåne, Sweden.
- Head of the clinical HD team at the Neurology clinic, Skåne University hospital, Lund.
- Head of the Huntington Disease Center, LU and Region Skåne (www.huntingtoncentrum.se)

4. Previous positions and periods of appointment

2016-2017	Professor in Medical Research with specialization in Neuroscience, Medical Faculty, LU
2012-2016	Senior Lecturer in Neuroscience (tenured position), Medical Faculty, LU
2009-2012	Senior researcher position at LU, 50%, funded by the Swedish Research Council
2007-2009	Junior researcher position at LU, funded by the Swedish Research Council
2007-2017	Residency in Psychiatry, the Psychiatric Clinic in Lund, Region Skåne
2005-2007	Internship at Blekinge Hospital, Karlshamn (total 21 months at 100%)
1997-2001	PhD student at the Medical Faculty, Lund University

5. Current grant support

Knut and Alice Wallenberg Foundation: Wallenberg Clinical Scholar (PI: Petersen)
Title: *Huntington disease- towards novel treatments for psychiatric symptoms*
Duration: 2020-2025. Level of support: 15 000 000 SEK

Swedish Research Council (PI: Petersen)
Title: *Effects of hypothalamic circuitries in Huntington disease*
Duration: 2019-2022. Level of support: 4 800 000 SEK

ALF: Regional Clinical Research Grants (PI: Petersen)
Title: *Effects of hypothalamic circuits in Huntington disease*
Duration: 2019-2022. Level of support: 5 800 000 SEK

Swedish Brain Foundation (PI: Petersen)
Title: *The role of hypothalamic pathology for ALS*
Duration: 2020-2022. Level of support: 1 200 000 SEK

6. Commissions of trust: Selected

- Head of the Huntington Disease Center, Excellence Center at LU and Region Skåne (since 2017: huntingtoncentrum.se)

- Member of the grant committee for the Norwegian Research Council: Translational Mental Health panel (2022)
- Member of the grant committee for the Swedish Research Council: Mental health panel (2021)
- Member of the scientific committee for the Swedish Brain Foundation (2021-)
- Member of the grant committee for the Swedish Society of Medicine (2019-2021)
- Associate Editor of *Journal of Huntington's Disease* (2019-)
- Editorial Board member of *Journal of Huntington's Disease* (2012-)
- Member of the Scientific and Bioethics Advisory Committee of the EHDN (2010-2014)

7. Publication list

Total number of publications: 112 (88 original research articles and 24 reviews/book chapters/commentaries)

Selected 10 key publications

1. Soylu-Kucharz R, Khoshnan A, **Petersén Å**. IKKβ signaling mediates metabolic changes in the hypothalamus of a Huntington disease mouse model. iScience 25:103771 (2022).
2. Gabery S, Kwa JE, Cheong RY, Baldo B, Ferrari Bardile C, Tan B, McLean C, Georgiou-Karistianis N, Poudel GR, Halliday G, Pouladi MA, **Petersén Å**. Early white matter pathology in the fornix of the limbic system in Huntington disease. Acta Neuropathologica 142: 791-806 (2021).
3. Gabery S, Ahmed RM, Caga J, Kiernan MC, Halliday GM, **Petersén Å**. Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology 47:979-989 (2021).
4. Cheong RY, Baldo B, Sajjad MU, Kirik D, **Petersén Å**. Effects of mutant huntingtin inactivation on Huntington disease-related behaviours in the BACHD mouse model. Neuropathology and Applied Neurobiology 47:564-578 (2021).
5. Cheong RY, Tonetto S, von Hörsten S, **Petersén Å**. Imbalance of the oxytocin-vasopressin system contributes to the neuropsychiatric phenotype in the BACHD mouse model of Huntington disease. Psychoneuroendocrinology 119:104773 (2020).
6. Baldo B, Gabery S, Soylu-Kucharz R, Cheong RY, Henningsen JB, McLean C, Kirik D, Halliday G, **Petersén Å**. *SIRT1* is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease. Neuropathology and Applied Neurobiology, 45: 361-379 (2019).
7. Siebzehnrubl F, Raber KA, Urbach YK, Schulze-Krebs A, Canneva F, Moceri S, Habermeyer J, Achoui D, Gupta B, Steindler DA, Stephan M, Nguyen H, Bonin M, Riess O, Bauer A, Aigner L, Couillard-Despres S, Paucar MA, Svenningsson P, Osmand A, Andreew A, Zabel C, Weiss A, Kuhn R, Moussaoui S, Blockx I, Van der Linden A, Cheong RY, Roybon L, **Petersén Å**, von Hörsten S. Early postnatal behavioral, cellular and molecular changes in models of Huntington disease are reversible by HDAC inhibition. Proceedings of the National Academy of Sciences USA, 115: E8765-E8774 (2018).
8. Hult Lundh S, Nilsson N, Soylu R, Kirik D, **Petersén Å**. Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease. Human Molecular Genetics 22:3485-3497 (2013).
9. Hult S, Soylu R, Björklund T, Belgardt BF, Mauer T, Bruning JC, Kirik D. **Petersén Å**. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metabolism. 13: 428-439 (2011).
10. Gabery S, Murphy K, Schultz K, Loy CT, McCusker E, Kirik D, Halliday G, **Petersén Å**. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathologica 120: 777-88 (2010).